Praxis Precision Medicine options signal ahead of two FDA decisions

The options market on Praxis Precision Medicines (PRAX) is signaling a significant event in the next four-to-five months, as the stock trades at $285.79, 27% below its 52-week high of $392.70. The primary structure, a 1,000 × 1,000 Feb. 19, 2027 $290/$450 call spread, makes up 78% of all call volume today. The $290 strike is at-the-money, needing only a 1.5% increase to become profitable, while the $450 leg caps the maximum profit but reduces the net premium cost.

The near-zero open interest (4 contracts) on the $290 leg indicates a new directional position, betting on the upside. This expiry is strategically placed to encompass two binary PDUFA events, with Raymond James raising its price target to $945 and H.C. Wainwright holding a $1,245 target. Despite the aggressive $450 call spread ceiling, it remains below the most bullish analyst targets, suggesting a mildly constructive market perception of upside and downside risk.

However, PRAX is down -17.1% over the last month and -1.62% YTD, having fallen from its highs. The recent missed primary endpoint in its POWER1 vormatrigine trial in June 2026 serves as a reminder that binary catalyst bets can quickly turn unfavorable. This binary event spread offers low-cost, high-leverage positioning, winning if Praxis clears one or both FDA hurdles, and potentially even more so if both do. The lack of prior open interest on the $290 leg confirms fresh conviction, not a hedge.